{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-053961","form_type":"8-K","ticker":"OFIX","cik":"0000884624","company_name":"Orthofix Medical Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.295582+00:00","generated_at":"2026-06-02T21:27:54.480157+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Orthofix Q1: net sales $188.6M (+7.7%), net loss narrows to $36M; raises FY sales outlook to $790-795M","bullets":["Net sales $188.6M, +7.7% YoY; Bone Growth Therapies +10%, U.S. Spine Fixation +16%, U.S. Orthopedics +23%.","GAAP net loss $(36.0)M ($0.95 loss per share) vs $(60.9)M ($1.71) prior year; adjusted EBITDA $7.7M (4.1% of sales).","FY2024 net sales guidance raised to $790-795M (from $785-795M); adjusted EBITDA guidance reaffirmed at $62-67M.","Cash and cash equivalents $29.5M; $125M drawn on $150M credit facility."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-053961","json":"https://secwatch.observer/filing/0000950170-24-053961.json","markdown":"https://secwatch.observer/filing/0000950170-24-053961.md","text":"https://secwatch.observer/filing/0000950170-24-053961.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/884624/000095017024053961/0000950170-24-053961-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/884624/000095017024053961/ofix-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T21:27:54.480157+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"03ecbc02f5984a634fc907a1b8c6bfd4001828b8","claim":"Orthofix Medical Inc. reported the first quarter ended March 31, 2024 results: revenue $188.6 million, net income $(36.0) million, EPS $(0.95). Guidance raised.","evidence_excerpt":"assets, and any impairment of acquired goodwil --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Orthofix Reports First Quarter 2024 Results Recent Highlights • Net sales of $188.6 million, an increase of 7.7% on a reported basis and 7.5% on a constant currency basis over prior year • Bone Growth Therapies net sales growth of 10%, marking five consecutive quarters","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/884624/000095017024053961/0000950170-24-053961-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$188.6 million"},{"label":"Net income","value":"$(36.0) million"},{"label":"EPS","value":"$(0.95)"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}